Overview

MSC for Occlusive Disease of the Kidney

Status:
Completed

Trial end date:
2017-04-01

Target enrollment:

Participant gender:

Summary

To determine the safety and toxicity of intra-arterial infused autologous adipose derived mesenchymal stromal (stem) cells in patients with vascular occlusive disease of the kidney.

Phase:

Phase 1

Details

Lead Sponsor:

Mayo Clinic